Literature DB >> 30694925

Neurological profiles beyond the sleep disorder in patients with anti-IgLON5 disease.

Carles Gaig1, Yaroslau Compta2.   

Abstract

PURPOSE OF REVIEW: Anti-IgLON5 disease is a novel entity characterized by a distinctive sleep disorder associated with a variety of neurological symptoms, antibodies against IgLON5, and pathological findings of neuronal tauopathy. The characteristic sleep disorder occurs in most patients, but other neurological symptoms are also important because they can be the presenting and most disabling problem and mimic other conditions. This review focuses on nonsleep neurological symptoms and presentations of anti-IgLON5 disease. RECENT
FINDINGS: Apart from sleep problems, the most frequent neurological symptoms in anti-IgLON5 disease are bulbar dysfunction and gait abnormalities. Other symptoms include movement disorders like chorea or abnormal orofacial movements, oculomotor abnormalities, cognitive impairment, and symptoms of nervous system hyperexcitability. All these symptoms can present in different combinations and severity leading to distinct clinical phenotypes beyond the sleep disorder: bulbar syndrome; syndrome resembling progressive supranuclear palsy; cognitive impairment, sometimes with chorea, mimicking Huntington disease; gait ataxia; and stiff-person-like syndrome.
SUMMARY: These clinical presentations may suggest degenerative or other neurological disorders, but anti-IgLON5 disease has to be considered, and confirmed by the detection of IgLON5 antibodies, when the criteria for the diagnosis of the initially suspected disorders are not fulfilled, confirmatory laboratory tests are negative, and significant sleep problems are present.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30694925     DOI: 10.1097/WCO.0000000000000677

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  9 in total

1.  Motor-neuron-disease-like phenotype associated with IgLON5 disease.

Authors:  Sri Raghav Sista; Brian Crum; Albert Aboseif; Michelle F Devine; Anastasia Zekeridou; M Bakri Hammami; Mohammed M Rezk; André Truffert; Patrice H Lalive; Amy Kunchok; Andrew McKeon; Divyanshu Dubey
Journal:  J Neurol       Date:  2022-07-20       Impact factor: 6.682

2.  Who to Enroll in Parkinson Disease Prevention Trials? The Case for Composite Prodromal Cohorts.

Authors:  Samantha A Molsberry; Katherine C Hughes; Michael A Schwarzschild; Alberto Ascherio
Journal:  Neurology       Date:  2022-08-16       Impact factor: 11.800

3.  Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease.

Authors:  Carles Gaig; Yaroslau Compta; Anna Heidbreder; Maria J Marti; Maarten J Titulaer; Yvette Crijnen; Birgit Högl; Jan Lewerenz; María Elena Erro; Juan Carlos Garcia-Monco; Pasquale Nigro; Nicola Tambasco; Maja Patalong-Ogiewa; Marcus Erdler; Stefan Macher; Evelyn Berger-Sieczkowski; Romana Höftberger; Christian Geis; Markus Hutterer; Angela Milán-Tomás; Antonio Martin-Bastida; Lydia Lopez Manzanares; Sonia Quintas; Günter U Höglinger; Nora Möhn; Florian Schoeberl; Franziska S Thaler; Gian Maria Asioli; Federica Provini; Giuseppe Plazzi; Koldo Berganzo; Morten Blaabjerg; Norbert Brüggemann; Tarsis Farias; Chen Fei Ng; Caroline Giordana; Alejandro Herrero-San Martín; Lucio Huebra; Katya Kotschet; Herburg Liendl; Teresa Montojo; Carlos Morata; Jesus Perez Perez; Inmaculada Puertas; Thomas Seifert-Held; Caspar Seitz; Mateus Mistieri Simabukuro; Nieves Tellez; Javier Villacieros-Álvarez; Barbara Willekens; Lidia Sabater; Alex Iranzo; Joan Santamaria Cano; Josep Dalmau; Francesc Graus
Journal:  Neurology       Date:  2021-08-11       Impact factor: 11.800

4.  An Elderly Man With Chaotic Sleep Behaviors and Rapidly Progressive Ataxia.

Authors:  Tittaya Prasertpan; Warongporn Phuenpathom; Roongroj Bhidayasiri; Jirada Sringean
Journal:  Mov Disord Clin Pract       Date:  2022-09-11

5.  Early immunotherapy is highly effective in IgG1/IgG4 positive IgLON5 disease.

Authors:  Thomas Grüter; Volker Behrendt; Corinna I Bien; Ralf Gold; Ilya Ayzenberg
Journal:  J Neurol       Date:  2020-05-22       Impact factor: 4.849

Review 6.  Anti-IgLON5 Disease - The Current State of Knowledge and Further Perspectives.

Authors:  Natalia Madetko; Weronika Marzec; Agata Kowalska; Dominika Przewodowska; Piotr Alster; Dariusz Koziorowski
Journal:  Front Immunol       Date:  2022-03-01       Impact factor: 7.561

7.  Anti-IGLON5 disease: A new case without neuropathologic evidence of brainstem tauopathy.

Authors:  Maria Elena Erro; Lidia Sabater; Laura Martínez; María Herrera; Aiora Ostolaza; Iñaki García de Gurtubay; Teresa Tuñón; Francesc Graus; Ellen Gelpi
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-12-11

8.  Pilot Study of the Effects of Chronic Intracerebroventricular Infusion of Human Anti-IgLON5 Disease Antibodies in Mice.

Authors:  Sara Alvente; Gabriele Matteoli; Laura Molina-Porcel; Jon Landa; Mercedes Alba; Stefano Bastianini; Chiara Berteotti; Francesc Graus; Viviana Lo Martire; Lidia Sabater; Giovanna Zoccoli; Alessandro Silvani
Journal:  Cells       Date:  2022-03-17       Impact factor: 6.600

Review 9.  Autoimmune encephalitis: clinical spectrum and management.

Authors:  Christopher E Uy; Sophie Binks; Sarosh R Irani
Journal:  Pract Neurol       Date:  2021-06-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.